The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 16, 2024 in Xiao-I Corporation Lawsuit - AIXI
- 25
PR Newswire
NEW YORK, Nov. 22, 2024
NEW YORK, Nov. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Xiao-I Corporation (NASDAQ: AIXI).
Shareholders who purchased shares of AIXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/xiao-i-corporation-loss-submission-form/?id=112969&from=4
CLASS PERIOD: March 9, 2023 to July 12, 2024
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) defendants had downplayed the true scope and severity of risks that Xiao-I faced due to certain of its Chinese shareholders' non-compliance with foreign investment enterprises established by way of round-tripping, including the Company's inability to use offering proceeds for intended business purposes; (ii) Xiao-I had failed to comply with Generally Accepted Accounting Principles in preparing its financial statements; (iii) defendants had overstated Xiao-I's efforts to remediate material weaknesses in the Company's financial controls; (iv) Xiao-I was forced to incur significant R&D expenses to effectively compete in the AI industry; (v) Xiao-I had downplayed the significant negative impact that such expenses would have on the Company's business and financial results; (vi) accordingly, Xiao-I overstated its AI capabilities, R&D resources, and overall ability to compete in the AI market; (vii) as a result of all the foregoing, there was a substantial likelihood that Xiao-I would fail to comply with the NASDAQ's Minimum Bid Price Requirement; and (viii) as a result, the offering documents and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
DEADLINE: December 16, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/xiao-i-corporation-loss-submission-form/?id=112969&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of AIXI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 16, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-december-16-2024-in-xiao-i-corporation-lawsuit--aixi-302313644.html
SOURCE The Gross Law Firm
![](https://rt.prnewswire.com/rt.gif?NewsItemId=NY63971&Transmission_Id=202411220545PR_NEWS_USPR_____NY63971&DateId=20241122)
PR Newswire est une agence de presse américaine, située à New York spécialisée dans la publication de communiqués de presse.
- Samsung Bioepis obtient l'approbation de la Commission européenne pour le biosimilaire du denosumab (OBODENCE™, XBRYK™)
- Venture Global, Inc. annonce le calendrier de la publication des résultats du quatrième trimestre et de l'exercice 2024 ainsi que de la conférence téléphonique
- Le prix Asa Gudmundsdottir Wright est présenté comme un projet pour la nouvelle Académie islandaise des sciences et de l'innovation
- Riskified présentera ses résultats financiers du quatrième trimestre et de l'exercice 2024 le mercredi 5 mars
- GENFIT annonce la modification des termes définitifs de la double proposition aux porteurs d’OCEANEs 2025
- Selon InfoLink Consulting, AESC occupe la quatrième place dans les livraisons mondiales de cellules de stockage d'énergie en 2024